Skip to main content

CCTG Oral & Plenary Presentations at ASCO 2023

CCTG Oral & Plenary Presentations at ASCO 2023

The ASCO 2023 General Meeting takes place June 2-6 in Chicago where global cancer experts discover the latest innovations in cancer research and education attending ground breaking clinical trial oral presentations that include CCTG studies IND227 and CX5. Here are is the list of the CCTG trials that will presenting this weekend.


IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.

Oral Abstract

Authors: Quincy Chu, Maria Carmela Piccirillo, Laurent Greillier, Federica Grosso, Giuseppe Lo Russo, Marie Florescu, Manlio Mencoboni, Penelope Bradbury, Alessandro Morabito, Fabiana Letizia Cecere, Sara Delfanti, Arnaud Scherpereel, Myriam Locatelli-Sanchez, Gerard Zalcman, David Dawe, Joana Sederias, Scott Laurie, Christopher Lee, Wei Tu, Lesley Seymour.



An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC). A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE)

Clinical Science Symposium (Oral)
Session Title: Knives Out: Surgical Management of Gynecologic Cancers

Authors: Marie Plante, Janice Kwon, Sarah Ferguson, Vanessa Samouëlian, Gwenael Ferron, Amandine Maulard, Cor de Kroon, Willemien Van Driel, John Tidy, Christian Marth, Karl Tamussino, Stefan Kommoss, Frederic Goffin, Brynhildur Eyjólfsdóttir, Jae-Weon Kim, Noreen Gleeson, Juliana M Ubi, Lori Brotto, Dongsheng Tu, Lois Shepherd


CCTG HDC1 (S1826 )

SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)


Authors: Alex Herrera, Michael LeBlanc, Sharon Castellino, Hongli Li, Sarah Rutherford, Andrew Evens, Kelly Davison, Angela Punnett, David Hodgson, Susan Parsons, Sairah Ahmed, Carla Casulo, Nancy Bartlett, Joo Song, Richard Little, Brad Kahl, John Leonard, Kara Kelly, Sonali Smith, Jonathan Friedberg

CCTG CRC7 (N1048)

PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048)


Authors: Deborah Schrag, Qian Shi, Martin Weiser, Marc Gollub, Leonard Saltz, Benjamin Musher, Joel Goldberg, Tareq Al Baghdadi, Karyn Goodman, Robert McWilliams, Jeffrey Farma, Thomas George, Hagen Kennecke, Alan Venook, Eileen O'Reilly, Jeffrey Meyerhardt, Amylou Dueck, Ethan Basch, George Chang, Harvey Mamon



Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial

Oral Abstract

Authors: Charles Leath, Wei Deng, Loren Mell, Debra Richardson, Joan Walker, Laura Holman, Jayanthi Lea, Sudha Amarnath, Luis Santos-Reyes, Rebecca Arend, Jyoti Mayadev, Naresh Jegadeesh, Paul Disilvestro, Hye Sook Chon, Sharad Ghamande, Allison Quick, Junzo Chino, Helen Mackay, Carol Aghajanian, Bradley Monk

CCTG BLC1 (S1011)

SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer

Oral Abstract

Authors: Seth Lerner, Catherine Tangen, Robert Svatek, Siamak Daneshmand, Kamal Pohar, Eila Skinner, Anne Schuckman, Arthur Sagalowsky, Norm Smith, Ashish Kamat, Wassim Kassouf, Melissa Plets, Rick Bangs, Theresa Koppie, Ajjai Alva, Francisco La Rosa, Sumanta Pal, Adam Kibel, Daniel Canter, Ian Thompson